Current Report Filing (8-k)
September 17 2021 - 6:04AM
Edgar (US Regulatory)
0000882291
false
0000882291
2021-09-15
2021-09-15
0000882291
dei:FormerAddressMember
2021-09-15
2021-09-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 15, 2021
Aethlon Medical, Inc.
(Exact name of registrant as specified in its charter)
Nevada
|
|
001-37487
|
|
13-3632859
|
(State or other jurisdiction
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
of incorporation)
|
|
|
|
|
|
|
11555 Sorrento Valley Road, Suite 203
San Diego, California
|
|
92121
|
(Address of principal executive offices)
|
|
(Zip Code)
|
|
|
|
Registrant’s telephone number, including
area code: 858-459-7800
9635 Granite Ridge Drive, Suite 100, San Diego,
California
(Former name or former address, if changed since
last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class
|
Trading Symbol
|
Name of each exchange on which registered
|
Common Stock
|
AEMD
|
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Item 5.07
|
Submission of Matters to a Vote of Security Holders.
|
On September 15, 2021, Aethlon Medical, Inc. (the
“Company”) held its virtual 2021 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual
Meeting, the Company’s stockholders considered the two proposals listed below, each of which was described in the Proxy Statement.
The voting results are set forth below.
Proposal 1. Elect five members of the Board of Directors.
All of the nominees were elected.
Name
|
Votes For
|
Votes Against
|
Abstentions
|
Broker Non-Votes
|
Edward G. Broenniman
|
7,480,266
|
143,135
|
19,459
|
2,506,013
|
Guy F. Cipriani
|
7,372,780
|
250,178
|
19,902
|
2,506,013
|
Charles J. Fisher, Jr., M.D.
|
7,523,207
|
110,123
|
9,530
|
2,506,013
|
Sabrina Martucci Johnson
|
7,283,551
|
339,156
|
20,153
|
2,506,013
|
Chetan S. Shah, M.D.
|
7,512,445
|
116,097
|
14,318
|
2,506,013
|
Proposal 2. Ratify the appointment of Baker Tilly US, LLP
as the Company’s independent registered public accounting firm for its fiscal year ending March 31, 2022. The resolution was approved.
Votes For
|
Votes Against
|
Abstentions
|
Broker Non-Votes
|
10,105,396
|
35,971
|
7,506
|
2,506,013
|
No adjournment of the Annual Meeting was necessary.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
Aethlon Medical, Inc.
|
|
|
|
|
Dated: September 16, 2021
|
|
|
|
By:
|
|
/s/ James B. Frakes
|
|
|
|
|
|
|
James B. Frakes
Chief Financial Officer
|
Aethlon Medical (NASDAQ:AEMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aethlon Medical (NASDAQ:AEMD)
Historical Stock Chart
From Apr 2023 to Apr 2024